Technical Data
E3373-09F
EphB6, NT (S45) (Ephrin Type-A Receptor 6, Tyrosine-protein Kinase Receptor EPH-6, HEP)
Description:
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB6 lacks the kinase activity of most receptor tyrosine kinases and binds to ephrin-B ligands.

Applications:
Suitable for use in ELISA, Western Blot, Flow Cytometry, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100-1:500
ELISA: 1:1,000
Immunohistochemistry: 1:50-1:100
Flow Cytometry: 1:10-1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
200ul-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide selected from N-terminal region with serine at position 45 of human EphB6 (KLH).
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, 0.09% sodium azide.
Specificity:
Recognizes human EphB6.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Freywald, A., et al., J. Biol. Chem. 278(12):10150-10156 (2003). 2.Luo, H., et al., J. Clin. Invest. 110(8):1141-1150 (2002). 3.Wilkinson, D.G., Nat Rev Neurosci 2(3):155-164 (2001). 4.Luo, H., et al., J. Immunol. 167(3):1362-1370 (2001). 5.Tang, X.X., et al., Proc. Natl. Acad. Sci. USA 97(20):10936-10941 (2000). 6.Jun Yu, et al. Clin. Cancer Res., Apr 2010; 16: 2275-2283.(E-pub)